Search research articles
Contact Us
Filters
Showing results (131-140 of 164) with videos related to
Page
of 17
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 2, 2012
Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors
Ian Krop, Tim Demuth, Tina Guthrie, et al.
Investigational New Drugs
|
April 26, 2019
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
Geoffrey I Shapiro, Patricia LoRusso, Eunice Kwak, et al.
British Journal of Cancer
|
May 26, 2018
Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials
Tomoya Yokota, Johanna Bendell, Patricia LoRusso, et al.
Clinical Trials (London, England)
|
February 26, 2026
Shaping the future of clinical trials through strategic foresight
Sharon Lee, Jeff McIntyre, Tracey Robertson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 8, 2017
A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i>-Mutated Ovarian Carcinoma or Other Solid Tumors
Rebecca Kristeleit, Geoffrey I Shapiro, Howard A Burris, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
July 31, 2012
Dogs are more sensitive to antagonists of inhibitor of apoptosis proteins than rats and humans: a translational toxicokinetic/toxicodynamic analysis
Harvey Wong, Nageshwar R Budha, Kristina West, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2019
Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies
Gerald Falchook, Seth Rosen, Patricia LoRusso, et al.
Clinical and Translational Science
|
May 23, 2026
Safety and Efficacy of HexaBody-DR5/DR5 in Malignant Solid Tumors: Phase 1/2a Results and Translational Insights Into Observed Hepatotoxicity
Marije B Overdijk, Kristin Strumane, Ruth Plummer, et al.
Journal for Immunotherapy of Cancer
|
July 24, 2021
CX-072 (pacmilimab), a Probody <b></b> PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study
Aung Naing, Fiona Thistlethwaite, Elisabeth G E De Vries, et al.
Cell Reports. Medicine
|
February 11, 2025
Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers
Stephane Champiat, Elena Garralda, Vladimir Galvao, et al.
Page
of 17
Search research articles
Search
Showing results (131-140 of 164) with videos related to
Sort By:
Page
of 17
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 2, 2012
Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors
Ian Krop, Tim Demuth, Tina Guthrie, et al.
Investigational New Drugs
|
April 26, 2019
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
Geoffrey I Shapiro, Patricia LoRusso, Eunice Kwak, et al.
British Journal of Cancer
|
May 26, 2018
Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials
Tomoya Yokota, Johanna Bendell, Patricia LoRusso, et al.
Clinical Trials (London, England)
|
February 26, 2026
Shaping the future of clinical trials through strategic foresight
Sharon Lee, Jeff McIntyre, Tracey Robertson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 8, 2017
A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i>-Mutated Ovarian Carcinoma or Other Solid Tumors
Rebecca Kristeleit, Geoffrey I Shapiro, Howard A Burris, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
July 31, 2012
Dogs are more sensitive to antagonists of inhibitor of apoptosis proteins than rats and humans: a translational toxicokinetic/toxicodynamic analysis
Harvey Wong, Nageshwar R Budha, Kristina West, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2019
Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies
Gerald Falchook, Seth Rosen, Patricia LoRusso, et al.
Clinical and Translational Science
|
May 23, 2026
Safety and Efficacy of HexaBody-DR5/DR5 in Malignant Solid Tumors: Phase 1/2a Results and Translational Insights Into Observed Hepatotoxicity
Marije B Overdijk, Kristin Strumane, Ruth Plummer, et al.
Journal for Immunotherapy of Cancer
|
July 24, 2021
CX-072 (pacmilimab), a Probody <b></b> PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study
Aung Naing, Fiona Thistlethwaite, Elisabeth G E De Vries, et al.
Cell Reports. Medicine
|
February 11, 2025
Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers
Stephane Champiat, Elena Garralda, Vladimir Galvao, et al.
Page
of 17